Essential Reads: Zuranolone for Postpartum Depression
Zuranolone has antidepressant effects in women with severe PPD, observed as early as 3 days after initiation of treatment. Â
Recruiting New Mothers with Postpartum Depression for the Skylark Study
In 2019, brexanolone was introduced by Sage Therapeutics as Zulresso, a novel treatment for postpartum depression. The oral version of this novel antidepressant – SAGE 217 or zuranolone – is now finishing up its Phase [...]
A Novel Treatment for PMDD: Ulipristal Acetate, a Progesterone Receptor Modulator
While many women experience physical symptoms prior to the onset of their period or premenstrual syndrome (PMS), a smaller subset of women suffer from Premenstrual Dysphoric Disorder (PMDD), a more severe form of premenstrual [...]
In Brief: Gabapentin (Neurontin) for the Treatment of Hyperemesis Gravidarum
While the majority of pregnant women experience nausea and/or vomiting during the first trimester of pregnancy, a smaller subset of women — around 1% — experience more severe and intractable vomiting, or hyperemesis gravidarum [...]
Low-Dose Testosterone for Depression in Women: Does It Work?
In women, testosterone is produced by the ovaries in small amounts; however, levels of testosterone decline with age, independent of menopausal status. Low-dose testosterone has been used to improve sexual functioning in women with [...]
More Data on the Neuroactive Steroid Zuranolone for Postpartum Depression
While we have heard a lot about brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant – SAGE 217 or zuranolone – has been [...]
Ondansetron (Zofran) for Nausea and Vomiting in Pregnancy: Maybe Not for All Women
Nausea and vomiting of pregnancy (NVP) affects up to 80% of women during the first trimester. A smaller proportion of women (0.3%–3.0%) experience severe vomiting or hyperemesis gravidarum. While milder cases of nausea and [...]
Development of Zuranolone (SAGE 217) for PPD Will Move Forward
Zuranolone or SAGE-217 is similar to brexanolone (marketed as Zulresso), the medication which was FDA-approved for the treatment of postpartum depression. Zuranolone is a neurosteroid, an analogue of allopregnanolone, which is a positive allosteric [...]
Allopregnanolone Sparks Interest as New PMDD Treatment
Sepranolone is a neuroseroid now in Phase II clinical trials for the treatment of premenstrual dysphoric disorder (PMDD). Â
Don’t Forget About Brexanolone’s Little Sister: Zuranolone
While we have been talking about using brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant - SAGE 217 or zuranolone - has [...]